NGNE
Price
$22.92
Change
+$1.25 (+5.77%)
Updated
Jun 5 closing price
Capitalization
327.6M
SNDX
Price
$11.16
Change
+$0.20 (+1.82%)
Updated
Jun 5 closing price
Capitalization
960.29M
66 days until earnings call
Interact to see
Advertisement

NGNE vs SNDX

Header iconNGNE vs SNDX Comparison
Open Charts NGNE vs SNDXBanner chart's image
Neurogene
Price$22.92
Change+$1.25 (+5.77%)
Volume$335.62K
Capitalization327.6M
Syndax Pharmaceuticals
Price$11.16
Change+$0.20 (+1.82%)
Volume$1.11M
Capitalization960.29M
NGNE vs SNDX Comparison Chart
Loading...
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NGNE vs. SNDX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NGNE is a Buy and SNDX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (NGNE: $22.97 vs. SNDX: $11.16)
Brand notoriety: NGNE and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NGNE: 108% vs. SNDX: 45%
Market capitalization -- NGNE: $327.6M vs. SNDX: $960.29M
NGNE [@Biotechnology] is valued at $327.6M. SNDX’s [@Biotechnology] market capitalization is $960.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NGNE’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • NGNE’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, both NGNE and SNDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NGNE’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 6 bullish TA indicator(s).

  • NGNE’s TA Score: 6 bullish, 3 bearish.
  • SNDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NGNE is a better buy in the short-term than SNDX.

Price Growth

NGNE (@Biotechnology) experienced а +22.57% price change this week, while SNDX (@Biotechnology) price change was +5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

NGNE is expected to report earnings on May 09, 2025.

SNDX is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($960M) has a higher market cap than NGNE($328M). NGNE YTD gains are higher at: 0.481 vs. SNDX (-15.582). NGNE has higher annual earnings (EBITDA): -77.68M vs. SNDX (-318.27M). SNDX has more cash in the bank: 516M vs. NGNE (293M). SNDX has less debt than NGNE: SNDX (1.84M) vs NGNE (13.5M). SNDX has higher revenues than NGNE: SNDX (43.7M) vs NGNE (925K).
NGNESNDXNGNE / SNDX
Capitalization328M960M34%
EBITDA-77.68M-318.27M24%
Gain YTD0.481-15.582-3%
P/E RatioN/AN/A-
Revenue925K43.7M2%
Total Cash293M516M57%
Total Debt13.5M1.84M735%
FUNDAMENTALS RATINGS
NGNE vs SNDX: Fundamental Ratings
NGNE
SNDX
OUTLOOK RATING
1..100
1810
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9295
PRICE GROWTH RATING
1..100
4190
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (70) in the null industry is in the same range as SNDX (84) in the Biotechnology industry. This means that NGNE’s stock grew similarly to SNDX’s over the last 12 months.

NGNE's Profit vs Risk Rating (100) in the null industry is in the same range as SNDX (100) in the Biotechnology industry. This means that NGNE’s stock grew similarly to SNDX’s over the last 12 months.

NGNE's SMR Rating (92) in the null industry is in the same range as SNDX (95) in the Biotechnology industry. This means that NGNE’s stock grew similarly to SNDX’s over the last 12 months.

NGNE's Price Growth Rating (41) in the null industry is somewhat better than the same rating for SNDX (90) in the Biotechnology industry. This means that NGNE’s stock grew somewhat faster than SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for NGNE (100) in the null industry. This means that SNDX’s stock grew significantly faster than NGNE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NGNESNDX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 22 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USEMX22.48N/A
N/A
Victory Emerging Markets
INRSX16.78N/A
N/A
Macquarie Natural Resources R6
FAPHX12.98N/A
N/A
Fidelity Healthy Future
IVIFX20.91N/A
N/A
Macquarie International Core Eq C
VGRIX78.36N/A
N/A
JPMorgan US Value A

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
+6.00%
BRNS - NGNE
51%
Loosely correlated
-8.33%
RNAZ - NGNE
48%
Loosely correlated
-1.89%
ZNTL - NGNE
47%
Loosely correlated
-2.00%
SNDX - NGNE
45%
Loosely correlated
+1.82%
IRON - NGNE
43%
Loosely correlated
+1.39%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+1.82%
IDYA - SNDX
52%
Loosely correlated
-0.09%
CGON - SNDX
52%
Loosely correlated
+0.23%
ETNB - SNDX
51%
Loosely correlated
-0.99%
KRYS - SNDX
49%
Loosely correlated
+0.53%
REPL - SNDX
48%
Loosely correlated
+0.62%
More